Skip to main content
Premium Trial:

Request an Annual Quote

Ingenium to Develop Mutant Animals for Oxagen

NEW YORK, June 5 - Ingenium Pharmaceuticals has signed an agreement with UKbiotech company Oxagen, to create animal models with defined gene alterations for research into metabolic diseases, the companies said.


The companies did not disclose the financial terms of the agreement.


The project will use Ingenium's genotyping platform to create mammalian models that carry alterations in target genes. Oxagen has identified genes relating to metabolic diseases using its target identification technology.

Ingenium is based in Munich.

The Scan

Follow-Up Data Requests to Biobank Participants Ineffective, Study Finds

An effort to recontact biobank enrollees for additional information reports low participation in a new BMJ Open study.

Study Finds Widespread Transmission of Resistant Bacteria in Vietnam Hospitals

A sequencing study in The Lancet Microbe finds widespread transmission of drug-resistant Escherichia coli, Klebsiella pneumoniae, and Acinetobacter baumannii in two Vietnam ICUs.

Novel Brain Cell Organoids Show Promise for Autism Research

University of Utah researchers report in Nature Communications on their development of brain cell organoids to study SHANK3-related autism.

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.